Pharmaceutical Executive-07-01-2010

In France, it took a president's keynote speech to underscore the government's new understanding that there is more to pharmaceuticals than cost-containment

Focus Reports discusses kep questions regarding France's pharma industry

FDA's risk-reduction requirements could be the bridge to a bright new future for the pharma industry.

As they build market share, companies need a plan to limit exposure to steep fines and executive prosecutions.

Outsourcing the sales representative function can help pharmaceutical companies build on their bottom line.

Drug prices, doctor payments, and FDA regulatory decisions are candidates for expanded disclosure.

Once occupied by a single pharma leader, the roles of CEO, president, and board chairman are increasingly being separated. What's behind the trend?

New strategies like augmented reality can increase patient compliance and knowledge.

Why do patients drop drug therapy after 12 months?

Pharma companies are starting to get back in the game with increased advertising spend in 2009. Do we have economic recovery to thank, or is there a deeper cause?

If there was ever a justification for endorsing a "triple bottom line" strategy for measuring Big Pharma's investment performance, it's the BP crisis.

Why pharma sales representatives are still the best marketers and how to make them better.